CR7849A - Agente para la prevencion o tratamiento de neuropatias - Google Patents

Agente para la prevencion o tratamiento de neuropatias

Info

Publication number
CR7849A
CR7849A CR7849A CR7849A CR7849A CR 7849 A CR7849 A CR 7849A CR 7849 A CR7849 A CR 7849A CR 7849 A CR7849 A CR 7849A CR 7849 A CR7849 A CR 7849A
Authority
CR
Costa Rica
Prior art keywords
agent
neuropathies
prevention
treatment
preventing
Prior art date
Application number
CR7849A
Other languages
English (en)
Inventor
Momomse Yu
Sakai Nozomu
Maekama Tsuyoshi
Kawamura Toru
Sera Misayo
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR7849A publication Critical patent/CR7849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65395—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)

Abstract

La presente invencion provee un agente para prevenir o tratar neuropatia que tiene una accion superior y baja toxicidad. Este agente comprende un compuesto representado por la formula: (I)
CR7849A 2002-11-01 2005-05-26 Agente para la prevencion o tratamiento de neuropatias CR7849A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002320153 2002-11-01

Publications (1)

Publication Number Publication Date
CR7849A true CR7849A (es) 2005-09-19

Family

ID=32211840

Family Applications (2)

Application Number Title Priority Date Filing Date
CR7849A CR7849A (es) 2002-11-01 2005-05-26 Agente para la prevencion o tratamiento de neuropatias
CR10127A CR10127A (es) 2002-11-01 2008-07-01 Agente para la prevención o tratamiento de neuropatías (divisional exp. 7849)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR10127A CR10127A (es) 2002-11-01 2008-07-01 Agente para la prevención o tratamiento de neuropatías (divisional exp. 7849)

Country Status (20)

Country Link
US (2) US7423159B2 (es)
EP (1) EP1556032A1 (es)
JP (1) JP2008231115A (es)
KR (1) KR20050062645A (es)
CN (1) CN1731994A (es)
AR (1) AR041867A1 (es)
AU (1) AU2003278600A1 (es)
BR (1) BR0315815A (es)
CA (1) CA2504511A1 (es)
CO (1) CO5570666A2 (es)
CR (2) CR7849A (es)
MX (1) MXPA05004505A (es)
NO (1) NO20052626L (es)
NZ (1) NZ540381A (es)
PE (1) PE20040609A1 (es)
PL (1) PL376733A1 (es)
RU (1) RU2337682C2 (es)
TW (1) TW200416029A (es)
WO (1) WO2004039365A1 (es)
ZA (1) ZA200503967B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339052B2 (en) * 2005-02-08 2008-03-04 Honeywell International Inc. Phosphoramidite activator for oligonucleotide synthesis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
ES2531118T5 (es) 2006-06-15 2022-06-14 Ucb Pharma Gmbh Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia
EP2039779A1 (en) 2006-07-19 2009-03-25 Takeda Pharmaceutical Company Limited Screening method
EP1939180A1 (en) * 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
IN2012DN00954A (es) 2009-07-28 2015-04-10 Takeda Pharmaceutical
KR101149821B1 (ko) 2010-04-05 2012-05-24 하나제약 주식회사 디페닐아세테이트 유도체의 새로운 제조방법
EA021698B1 (ru) 2010-04-27 2015-08-31 Такеда Фармасьютикал Компани Лимитед Производные бициклических соединений и их применение в качестве ингибиторов acc
PH12012502468A1 (en) 2010-06-16 2015-05-08 Takeda Pharmaceuticals Co Crystal of amide compound
EP2617726A4 (en) 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
EP2649062B1 (en) 2010-11-30 2015-04-08 Takeda Pharmaceutical Company Limited Bicyclic compounds as inhibitors of acetyl-coa carboxylase (acc)
RU2445066C1 (ru) * 2011-01-13 2012-03-20 Государственное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО АГМА Росздрава) Способ лечения невропатии лицевого нерва
BR112013020634A2 (pt) 2011-02-17 2016-10-25 Takeda Pharmaceutical método para produzir uma forma opticamente ativa de um composto, sal, complexo de rutênio, composto, e, cristal
CA2842364A1 (en) * 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
ES2954991T3 (es) 2011-07-29 2023-11-28 Karyopharm Therapeutics Inc Moduladores del transporte nuclear que contienen hidrazida y usos de los mismos
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
RU2486918C1 (ru) * 2011-10-25 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций
JP6129850B2 (ja) 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体
EP2816023A4 (en) 2012-02-13 2015-09-09 Takeda Pharmaceutical AROMATIC RING CONNECTION
US9181186B2 (en) 2012-02-13 2015-11-10 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
JP6106179B2 (ja) 2012-02-24 2017-03-29 武田薬品工業株式会社 芳香環化合物
CA2868713A1 (en) 2012-03-29 2013-10-03 Takeda Pharmaceutical Company Limited Aromatic ring compound
SMT202000347T1 (it) 2012-05-09 2020-07-08 Biogen Ma Inc Modulatori di trasporto nucleare e loro usi
EP2848622A4 (en) 2012-05-10 2015-11-04 Takeda Pharmaceutical Aromatic ring compound
EP2848621A4 (en) 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
AR092843A1 (es) 2012-06-05 2015-05-06 Takeda Pharmaceuticals Co Preparacion solida
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
JP6247697B2 (ja) 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
RU2538621C2 (ru) * 2013-05-08 2015-01-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ стимулирования восстановления иннервации тканей после травм и ишемии с помощью векторной конструкции
PL3010892T3 (pl) 2013-06-21 2019-07-31 Karyopharm Therapeutics, Inc. 1,2,4-triazole jako modulatory transportu jądrowego i ich zastosowania
CA2917490A1 (en) 2013-07-09 2015-01-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6397410B2 (ja) 2013-08-09 2018-09-26 武田薬品工業株式会社 芳香環化合物
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
ITMI20132201A1 (it) 2013-12-23 2015-06-24 Isagro Spa Processo per la sintesi regioselettiva di pirazoli
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015155713A1 (en) 2014-04-09 2015-10-15 Isagro S.P.A. Process for the regioselective synthesis of 1,3, 4 -substituted pyrazoles
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
JPWO2018181847A1 (ja) 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EA202092269A1 (ru) 2018-03-23 2020-12-14 Кармот Терапьютикс, Инк. Модуляторы сопряженных с g-белком рецепторов
JP6773938B2 (ja) 2018-08-27 2020-10-21 株式会社スコヒアファーマ 安息香酸エステル化合物
EP3856768A2 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
EP3856339A1 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
EP3870578B1 (en) 2018-10-22 2023-08-16 C4x Discovery Limited Therapeutic compounds
GB201901559D0 (en) * 2019-02-05 2019-03-27 Syngenta Crop Protection Ag Herbicidal compositions
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
AR121649A1 (es) 2020-03-25 2022-06-22 Takeda Pharmaceuticals Co Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
AU2021241257A1 (en) 2020-03-25 2022-10-13 Takeda Pharmaceutical Company Limited QD dosing of GIP receptor agonist peptide compounds and uses thereof
PL4143183T3 (pl) 2020-04-29 2026-03-02 Gasherbrum Bio, Inc. Heterocykliczni agoniści glp-1
CN117980325A (zh) 2021-05-13 2024-05-03 卡莫特治疗学股份有限公司 G-蛋白偶联受体的调节剂
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2026501171A (ja) 2022-12-15 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態
WO2024126777A1 (en) * 2022-12-16 2024-06-20 Astrazeneca Ab Heteroaromatic compounds
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4638440A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
TW202521528A (zh) 2023-07-13 2025-06-01 美商雅空嘉閣生物公司 化合物、組合物及方法
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025154021A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702330A (en) * 1970-10-05 1972-11-07 Merck & Co Inc Imidazolyl acrylic acid derivatives
US4172136A (en) * 1975-12-23 1979-10-23 Boehringer Mannheim Gmbh 3-Nitropyrazole compounds and anti-microbial compositions
DE2739689C2 (de) * 1977-09-02 1986-10-16 Euratom Thermische Wärmepumpe
DE2853854A1 (de) * 1978-12-13 1980-07-03 Patra Patent Treuhand Leuchtstofflampen-set
DE3002413A1 (de) * 1980-01-24 1981-07-30 Hoechst Ag, 6000 Frankfurt N,n-dialkyl-o-(pyrazol-5-yl)-carbaminsaeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide
JPH064584B2 (ja) * 1984-02-29 1994-01-19 沢井製薬株式会社 新規アニリド誘導体
FI860755A0 (fi) 1984-06-22 1986-02-20 Sandoz Ag Pyrazolanaloger av mevolonolakton och deras derivat, foerfaranden foer deras framstaellning samt deras andvaendning.
US4835280A (en) * 1985-01-18 1989-05-30 Boehringer Mannheim Gmbh Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles
US5464860A (en) * 1988-11-30 1995-11-07 Novapharme N(pyrazol-3-yl) benzamides and pharmaceutical compositions
JPH04184435A (ja) 1990-11-20 1992-07-01 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料及びその処理方法
US5172136A (en) * 1991-09-06 1992-12-15 Eastman Kodak Company Color registration is scanning thermal printer
US5250504A (en) * 1991-11-20 1993-10-05 Fmc Corporation Herbicidal β-pyrazolylacrylic acids
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5552420A (en) * 1994-05-13 1996-09-03 Sterling Winthrop Inc. Therapeutic phenoxyalkylazoles and phenoxyalkylazines
JPH10195063A (ja) * 1996-10-21 1998-07-28 Dai Ichi Seiyaku Co Ltd エチニルチアゾール誘導体
US6545009B1 (en) 1998-07-01 2003-04-08 Takeda Chemical Industries, Ltd. Retinoid-related receptor function regulating agent
EP1148053A4 (en) * 1999-01-26 2002-03-06 Ono Pharmaceutical Co 2H-PHTHALAZIN-1-ON DERIVATIVES AND DRUG COMPOSITIONS THAT CONTAIN THESE DERIVATIVES AS ACTIVE INGREDIENTS
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
AU2002364549B2 (en) * 2001-12-10 2007-11-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
EP1486490A1 (en) 2002-02-28 2004-12-15 Takeda Chemical Industries, Ltd. Azole compounds
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity

Also Published As

Publication number Publication date
NZ540381A (en) 2007-11-30
US7423159B2 (en) 2008-09-09
JP2008231115A (ja) 2008-10-02
AR041867A1 (es) 2005-06-01
MXPA05004505A (es) 2005-07-26
WO2004039365A1 (en) 2004-05-13
KR20050062645A (ko) 2005-06-23
US20060004069A1 (en) 2006-01-05
PE20040609A1 (es) 2004-10-29
AU2003278600A1 (en) 2004-05-25
ZA200503967B (en) 2006-11-29
BR0315815A (pt) 2005-09-13
EP1556032A1 (en) 2005-07-27
NO20052626L (no) 2005-07-01
US20080287438A1 (en) 2008-11-20
NO20052626D0 (no) 2005-05-31
CN1731994A (zh) 2006-02-08
CA2504511A1 (en) 2004-05-13
PL376733A1 (pl) 2006-01-09
TW200416029A (en) 2004-09-01
RU2005116689A (ru) 2006-01-20
CR10127A (es) 2008-08-18
RU2337682C2 (ru) 2008-11-10
CO5570666A2 (es) 2005-10-31

Similar Documents

Publication Publication Date Title
CR7849A (es) Agente para la prevencion o tratamiento de neuropatias
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
AR023388A1 (es) INHIBIDORES DE aP2 DE BIFENILOS QUE CONTIENEN COMPUESTOS HETEROCICLICOS Y METODO DE TRATAMIENTO
AR027788A1 (es) Proceso de desinfectar una superficie dura con una composicion que comprende aceite de canela y/o un activo de este
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
ECSP066635A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
BRPI0517887A (pt) combinações de inibidores de jaks
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
CY1111246T1 (el) Προληψη και θεραπεια επαγομενης απο φλεγμονη και/ή ανοσοδιαμεσολαβουμενης οστικης απωλειας
GT200500179A (es) Mezclas sinergistas de agentes de antranilamida para el control de plagas de invertebrados
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
GT200300053A (es) Compuestos que modulan la actividad de ppar
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
GT200300054A (es) Compuestos que modulan la actividad de ppar
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
PT1587821E (pt) Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
AR026173A1 (es) Inhibidores de neuraminidasas.
SE9901272D0 (sv) New improved formulation
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
BRPI0417104A (pt) composto, processo para a preparação de um composto, composição fungicida e método para o combate preventivo ou curativo de fungos fitopatogênicos de plantações